Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours

(2014) F A L M Eskens et al.   BRITISH JOURNAL OF CANCER

Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors

(2013) C. Sessa et al.   CLINICAL CANCER RESEARCH

The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models

(2012) Céline Clémenson et al.   INVESTIGATIONAL NEW DRUGS

International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1

(2012) Giorgio V. Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer

(2011) M. Zweifel et al.   ANNALS OF ONCOLOGY

Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer

(2011) Primo N. Lara et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiovascular Toxicity Profiles of Vascular-Disrupting Agents

(2011) I. M. Subbiah et al.   ONCOLOGIST

Disrupting established tumor blood vessels

(2010) Mark J. McKeage et al.   CANCER

Carboplatin and Paclitaxel in Combination With Oral Enzastaurin in Advanced Ovarian or Primary Peritoneal Cancer

(2010) Ignace Vergote et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies

(2009) A. du Bois et al.   ANNALS OF ONCOLOGY